RxDoctor Payments Data

Yohannes Bayissa, MD

Interventional Cardiology · Mansfield, OHNPI 1093022451

Payments from drug & device makers

$30,689in general payments, 2019–2025

Across 278 payments — averaging $110.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$14K
  • Abiomed$5K
  • Medtronic$3K
  • Edwards Lifesciences$2K
  • Inari Medical, Inc.$2K
  • W. L. Gore & Associates, Inc.$1K
  • plus $3K from 18 others

What the payments were for

  • Consulting fees$2,0007%
  • Speaking & faculty fees$6,00020%
  • Travel & lodging$12,92742%
  • Food & beverage$9,74432%
  • Education$190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,689 in reported general payments places this provider in the 65th percentile of 256 interventional cardiology providers in Ohio.

See all interventional cardiology providers in Ohio

Medicare billing

Part B allowed, 2024
$163,770
Medicare patients
356
Services billed
753

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban131$131,910
BrilintaTicagrelor69$34,808
XareltoRivaroxaban28$22,654
JardianceEmpagliflozin11$6,322
ClopidogrelClopidogrel Bisulfate215$2,812
Metoprolol Succinate211$2,598
Ranolazine ErRanolazine17$2,198
Prasugrel Hcl17$1,514
Atorvastatin Calcium179$1,506
Isosorbide Mononitrate ErIsosorbide Mononitrate94$988
Potassium Chloride81$940
Diltiazem 24hr Er (Cd)Diltiazem Hcl35$800
Valsartan12$726
Bumetanide18$672
Warfarin Sodium73$547

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta$78$34,80869 claims
Johnson & JohnsonXarelto$151$22,65428 claims
Boehringer IngelheimJardiance$20$6,32211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 256 interventional cardiology providers in Ohio.

Other interventional cardiology in Mansfield

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →